AdaptHealth Sees FY2026 Sales $3.440B-$3.510B vs $3.441B Est
Benzinga Newsdesk 8 months ago
NewsGuidance
Guidance for Fiscal Year 2026While fourth quarter 2025 Adjusted EBITDA was impacted by a legal settlement expense of $14.5 million and over $10 million of strategic investments to accelerate onboarding the new capitated
Guidance for Fiscal Year 2026
While fourth quarter 2025 Adjusted EBITDA was impacted by a legal settlement expense of $14.5 million and over $10 million of strategic investments to accelerate onboarding the new capitated contract, the underlying earnings power of the business remains intact. As a result, the Company is providing its financial guidance for fiscal year 2026, as follows:
- Net revenue of $3.44 billion to $3.51 billion
- Adjusted EBITDA of $680 million to $730 million
- Free cash flow of $175 million to $225 million